ABSTRACT
This chapter summarizes the main systemic and topical drugs known to be associated with hypopigmentation. This adverse drug reaction is assumed to be relatively rare, and is most commonly associated with topical agents. Although drug-induced pigment loss usually results in a limited degree of morbidity, these changes may be very disturbing to the patient.
Over the last decade, dozens of novel therapeutic agents have been developed, including targeted cancer therapies, immunotherapy, and immunomodulatory drugs. Many of these drugs share the potential to cause cutaneous adverse reactions, including pigmentary disturbance. Enhancing dermatologists’ knowledge concerning differential diagnosis will greatly assist correct management of these conditions. In most cases of drug-induced hypopigmentation, no specific treatment is needed.
